Key result
Fusogenic nanoreactor-based EV miRNA detection clearly distinguishes healthy from atherosclerotic mice across disease stages.
Why the study?
Conventional methods for detecting extracellular vesicle microRNAs require EV lysis, which is expensive, labor-intensive, and time-consuming.
A novel fusogenic nanoreactor-based platform enables simple, in situ detection of EV miRNAs, successfully differentiating healthy from atherosclerotic mice.
Extracellular vesicle (EV) microRNAs (miRNAs) are critical liquid-biopsy biomarkers that facilitate noninvasive clinical diagnosis and disease monitoring. However, conventional methods for detecting these miRNAs require EV lysis, which is expensive, labor-intensive, and time-consuming. Inspired by natural viral infection mechanisms, a novel strategy is developed for detecting EV miRNAs in situ via vesicle fusion mediated by viral fusion proteins. A padlock probe encapsulated within fusogenic liposomes is activated by target miRNAs, thereby initiating a highly sensitive and specific rolling circle amplification (RCA) reaction. Three EV miRNAs associated with atherosclerosis are successfully analyzed using this method, thereby enabling clear differentiation of healthy and diseased mice at several disease stages. Overall, the developed platform offers a simple approach for detecting EV miRNAs and demonstrates significant potential for broad use in applications involving disease diagnosis and monitoring.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied Atherosclerosis. Fusogenic nanoreactor-based detection of EV miRNAs vs. Healthy mice was evaluated on Differentiation of healthy and diseased mice. Fusogenic nanoreactor-based detection of EV miRNAs enabled clear differentiation of healthy and diseased mice at several atherosclerosis stages.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: